A compound which has the formula: A-W-B-Y-therapeutic polypeptide wherein said polypeptide is a GLP-1 peptide comprising the amino acid sequence of formula: Xaa 7 -Xaa 8 -Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Xaa 18 -Tyr-Leu-Glu-Xaa 22 -Xaa 23 -Ala-Ala-Xaa 26 -Glu-Phe-Ile-Xaa 30 -Trp-Leu-Val-Xaa 34 -Xaa 35 -Xaa 36 -Xaa 37 -Xaa 38 Formula (SEQ ID No: 3) wherein Xaa 7 is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, N α -acetyl-histidine, α-fluoromethyl-histidine, α-methyl-histidine, 3-pyridylalanine, 2-pyridylalanine or 4-pyridylalanine; Xaa 8 is Ala, Gly, Val, Leu, Ile, Lys, Aib, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid; Xaa 18 is Ser, Lys or Arg; Xaa 22 is Gly, Glu or Aib; Xaa 23 is Gln, Glu, Lys or Arg; Xaa 26 is Lys, Glu or Arg; Xaa 30 is Ala, Glu or Arg; Xaa 34 is Lys, Glu or Arg; Xaa 35 is Gly or Aib; Xaa 36 is Arg or Lys; Xaa 37 is Gly, Ala, Glu or Lys; Xaa 38 is Lys, amide or is absent; A is an albumin binding residue selected from the group consisting of where the chiral carbon atom is either R or S, where the chiral carbon atom is either R or S, where the two chiral carbon atoms independently are either R or S, where the two chiral carbon atoms independently are either R or S, and B is -(CH 2) l -O-[(CH 2) n -O] m -(CH 2) p -[C NH-(CH 2) l -O-[(CH 2) n -O] m -(CH 2) p] q -, where l, m, n, and p independently are 1-5, and q is 0-5; Y is a chemical group linking B and the therapeutic agent, selected from the group consisting of -C NH-, -NHC -, -C NHCH 2 -, -CH 2 NHC -, -OC NH -, -NHC O-, -C NHCH 2 -, CH 2 NHC -, -C CH 2 -, -CH 2 C -, -C CH=CH-, -CH=CHC -, -(CH 2) s -, -C -, -C O-, -OC -, -NHC - and -C NH-, wherein s is 0 or 1; and W is a chemical group linking A and B, selected from the group consisting of -C NH-, - NHC -, -C NHCH 2 -, -CH 2 NHC -, -OC NH -, -NHC O-, -C CH 2 -, -CH 2 C -, -C CH=CH-, -CH=CHC -, -(CH 2) s -, -C -, -C O-, -OC -, -NHC - and -C NH-, wherein s is 0 or 1; or a pharmaceutically acceptable salt thereof. said polypeptide is a GLP-1 peptide comprising the amino acid sequence of formula: Xaa 7 -Xaa 8 -Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Xaa 18 -Tyr-Leu-Glu-Xaa 22 -Xaa 23 -Ala-Ala-Xaa 26 -Glu-Phe-Ile-Xaa 30 -Trp-Leu-Val-Xaa 34 -Xaa 35 -Xaa 36 -Xaa 37 -Xaa 38 Formula (SEQ ID No: 3) wherein Xaa 7 is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, N α -acetyl-histidine, α-fluoromethyl-histidine, α-methyl-histidine, 3-pyridylalanine, 2-pyridylalanine or 4-pyridylalanine; Xaa 8 is Ala, Gly, Val, Leu, Ile, Lys, Aib, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid; Xaa 18 is Ser, Lys or Arg; Xaa 22 is Gly, Glu or Aib; Xaa 23 is Gln, Glu, Lys or Arg; Xaa 26 is Lys, Glu or Arg; Xaa 30 is Ala, Glu or Arg; Xaa 34 is Lys, Glu or Arg; Xaa 35 is Gly or Aib; Xaa 36 is Arg or Lys; Xaa 37 is Gly, Ala, Glu or Lys; Xaa 38 is Lys, amide or is absent; Xaa 7 is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, N α -acetyl-histidine, α-fluoromethyl-histidine, α-methyl-histidine, 3-pyridylalanine, 2-pyridylalanine or 4-pyridylalanine; Xaa 8 is Ala, Gly, Val, Leu, Ile, Lys, Aib, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid; Xaa 18 is Ser, Lys or Arg; Xaa 22 is Gly, Glu or Aib; Xaa 23 is Gln, Glu, Lys or Arg; Xaa 26 is Lys, Glu or Arg; Xaa 30 is Ala, Glu or Arg; Xaa 34 is Lys, Glu or Arg; Xaa 35 is Gly or Aib; Xaa 36 is Arg or Lys; Xaa 37 is Gly, Ala, Glu or Lys; Xaa 38 is Lys, amide or is absent; A is an albumin binding residue selected from the group consisting of where the chiral carbon atom is either R or S, where the chiral carbon atom is either R or S, where the two chiral carbon atoms independently are either R or S, where the two chiral carbon atoms independently are either R or S, and B is -(CH 2) l -O-[(CH 2) n -O] m -(CH 2) p -[C NH-(CH 2) l -O-[(CH 2) n -O] m -(CH 2) p] q -, where l, m, n, and p independently are 1-5, and q is 0-5; Y is a chemical group linking B and the therapeutic agent, selected from the group consisting of -C NH-, -NHC -, -C NHCH 2 -, -CH 2 NHC -, -OC NH -, -NHC O-, -C NHCH 2 -, CH 2 NHC -, -C CH 2 -, -CH 2 C -, -C CH=CH-, -CH=CHC -, -(CH 2) s -, -C -, -C O-, -OC -, -NHC - and -C NH-, wherein s is 0 or 1; and W is a chemical group linking A and B, selected from the group consisting of -C NH-, - NHC -, -C NHCH 2 -, -CH 2 NHC -, -OC NH -, -NHC O-, -C CH 2 -, -CH 2 C -, -C CH=CH-, -CH=CHC -, -(CH 2) s -, -C -, -C O-, -OC -, -NHC - and -C NH-, wherein s is 0 or 1; or a pharmaceutically acceptable salt thereof.